BACKGROUND: During the 1980s, the incidence of primary malignant brain and other
central nervous system tumors (hereafter called brain cancer) was reported to be increasing …

Background.—Under the auspices of the College of American Pathologists, a
multidisciplinary group of clinicians, pathologists, and statisticians considered prognostic …

Preclinical data suggest that some new anticancer agents directed at novel targets
demonstrate tumor growth inhibition but not tumor shrinkage. Such cytostatic agents may …

Background Men with high serum prostate specific antigen usually undergo transrectal
ultrasound-guided prostate biopsy (TRUS-biopsy). TRUS-biopsy can cause side-effects …

Anticancer cytotoxic agents go through a process by which their antitumor activity—on the
basis of the amount of tumor shrinkage they could generate—has been investigated. In the …

Summary Background In the Medical Research Council (MRC) COIN trial, the epidermal
growth factor receptor (EGFR)-targeted antibody cetuximab was added to standard …

BACKGROUND: The prostate-specific antigen test was approved by the US Food and Drug
Administration in 1986 to monitor the disease status in patients with prostate cancer and, in …

Purpose: Although 61% of new cases of cancer occur among the elderly, recent studies
indicate that the elderly comprise only 25% of participants in cancer clinical trials. Further …

Purpose: Prostate-specific antigen (PSA) is a glycoprotein that is found almost exclusively in
normal and neoplastic prostate cells. For patients with metastatic disease, changes in PSA …

Abstract Background and Methods. Lyme disease, caused by the tick-borne spirochete
Borrelia burgdorferi, is associated with a wide variety of neurologic manifestations. To define …